Stopping Ozempic Because of Cost: What to Know First

If you are stopping a GLP-1 medication because you can no longer afford it, the reason matters more than the fact. Money running out is not the same thing as a treatment failing. In a study of people who stopped semaglutide or tirzepatide↗ — sold in Canada as Ozempic, Wegovy, Mounjaro and Zepbound, among other brand names — close to half stopped for financial reasons: a plan denial, a discount coupon expiring, or the out-of-pocket price simply landing out of reach.

Some of what happens next is outside your control. Some of it gets decided in the days around your last dose, and that is the part worth spending attention on.

Stopping over cost is common, and it is not a willpower problem

Discontinuation is the norm rather than the exception. In a Danish population study following more than 77,000 people↗ who started semaglutide for weight loss without diabetes, reported at a European diabetes meeting in 2025, 52% had stopped by twelve months.

When half of everyone stops, the explanation is not personal character. It is some combination of side effects, supply, life circumstance, and — the single most common reason in the study above — price.

If you lost weight on the medication, the medication worked. What changed is your ability to keep paying for it. That is a budget problem, not a verdict on you, and it has different solutions than a clinical problem would.

In Canada, the cost of these medications is a structural problem

Obesity medicine in Canada sits in an awkward gap. Obesity is treated as a chronic condition by the profession, but it is not formally recognized as one by most governments and payers, and the 2025 Canadian pharmacotherapy guideline update↗ names that gap directly as something that limits access to treatment, including through medication costs.

The practical result is that public drug programs across the country largely do not fund medications for weight management. Obesity Canada's 2019 report card on access to obesity treatment for adults↗ graded provinces and territories F on exactly this point.

In Ontario specifically, the Ontario Drug Benefit program covers semaglutide only under limited-use criteria for type 2 diabetes, not for weight management. Workplace and extended health plans vary enormously, and many cover these drugs for diabetes but not for weight management. Coverage rules also change, and your pharmacist can tell you what applies to your exact product today. The mechanics of all of it — public coverage, private plans, what is and is not funded — are set out separately: how Ozempic coverage works in Ontario.

None of that sits within your control, which is the part worth holding onto.

Questions worth asking before your last dose

Whether to stop, continue, switch or change a dose is a decision for you and the clinician who prescribed the medication. Several of the questions below tend to get skipped in that conversation, and a few of them occasionally change the answer.

• Speak to your prescriber before you stop, not after. This matters most if the medication is also treating type 2 diabetes, because stopping can affect blood sugar control and other medications may need to be looked at in the same conversation.
• Ask your pharmacist to price the exact product and re-check your plan. Prices differ between products, doses and pharmacies, and plan criteria are sometimes reassessed.
• In Ontario, ask whether the Trillium Drug Program↗ applies to you. It is designed for households spending roughly 4% or more of after-tax income on prescription drugs, and it applies to medications covered under the Ontario Drug Benefit program. Whether your particular medication qualifies is something your pharmacist can confirm.
• Ask whether a manufacturer patient support program exists for the product you are on.
• Ask whether a different medication would be both clinically appropriate for you and more affordable. More than one medication is approved in Canada for chronic weight management, and they differ in price, coverage and how they are taken. The alternatives are set out in other options when a GLP-1 is not working out.

What changed in Canada in 2026

Health Canada authorized the country's first generic semaglutide injection in April 2026, and it reached the Canadian market in May. That first generic is approved for the treatment of type 2 diabetes. At the end of June 2026 Health Canada authorized a second generic semaglutide↗ — this one a generic of Wegovy, approved for chronic weight management. Further generic submissions are under review.

Generic competition usually brings prices down over time, though how far depends on how many manufacturers eventually enter the market rather than on any single approval.

Two limits are worth knowing before you get your hopes up. The weight-management generic was authorized only at the end of June 2026, and an authorization is not the same thing as a product sitting on your pharmacy's shelf at a price you have been quoted — your pharmacist can tell you what is actually stocked and what it costs today. And authorization is not coverage either: a drug being available at a lower price does not mean a plan will pay for it.

Whether any of this changes your particular situation is a question for your prescriber and your pharmacist.

The shortcut worth avoiding

When the authorized product is priced beyond what a household can absorb month after month, the pull toward a cheaper vial from an online seller, a compounding source or a med spa is entirely understandable. It is also the one part of this situation where the downside is genuinely dangerous.

Health Canada has warned↗ people not to buy or use unauthorized or counterfeit GLP-1 products, which have turned up in Canada both online and in stores. Products outside the regulated supply have not been assessed for safety, effectiveness or quality. They can contain too much active ingredient, too little, or none at all, and have been found contaminated with solvents, heavy metals, particles or microbes. Because these are injections, sterility failures add infection risk to all of that.

If cost has pushed you toward that market, say so out loud to your prescriber or pharmacist. They will have heard it before, and there may be a safer route to a similar place.

What usually happens after you stop

Appetite tends to return first, often within weeks, before the scale moves at all. Weight usually follows over the months after. Clinical trials of obesity medications consistently show weight returning when treatment stops, which is why the Canadian guidelines describe these medications as long-term treatment↗ rather than a course to be completed.

That is physiology, not backsliding, and it is the same pattern seen when any long-term treatment for a chronic condition is withdrawn: weight regain after stopping a GLP-1.

One thing worth stating plainly: restarting the medication later, if circumstances change and your prescriber agrees, is a perfectly good outcome. For a chronic condition, going back onto an effective treatment is ordinary medicine. It is not a relapse and it is not starting over.

Where surgery fits, honestly

Bariatric surgery is not a way out of a money problem, and it should not be sold as one.

Ontario does fund bariatric surgery publicly, through hospital-based programs accessed by physician referral↗. Those programs involve structured assessment and, in most parts of the province, a long wait. The Sleeve Clinic is private-pay and is not covered by OHIP; cost and financing information is on the pricing and financing page.

Surgery also carries its own ongoing costs. Lifelong vitamin and mineral supplementation, periodic blood work and long-term follow-up are part of the treatment, not optional extras — what long-term aftercare involves is laid out separately.

More to the point, cost is not a clinical reason to choose one treatment over another. Whether surgery is appropriate for a particular person depends on their health, their weight history and an individual assessment — never on what their drug plan decided. If you lost weight on the medication, that assessment weighs where your weight sits now, the highest BMI documented in your history, and the trajectory across both; a number that came down on treatment does not settle the question by itself. Some people reading this will be better served by a different medication, by a publicly funded program, or by staying on treatment they can afford. The Sleeve Clinic prescribes and co-manages weight-management medication as well as performing sleeve gastrectomy, so switching, restarting or building a plan around what you can actually sustain is a conversation the clinic can have rather than a reason to look elsewhere. Being private-pay, it cannot make a drug your plan refuses to fund any cheaper. If you want to understand how the two treatments actually compare on their merits, that comparison sits here: weight-loss medication compared with bariatric surgery.

Common questions

Is it dangerous to stop a GLP-1 suddenly because I cannot afford it?

For most people stopping is not a medical emergency, but it should be a conversation rather than a decision made alone — particularly if the medication is also treating type 2 diabetes, where blood sugar control and other medications may need attention at the same time.

Will I gain all the weight back?

Some regain is usual and the amount varies a great deal between individuals. Appetite typically returns before the weight does. Neither is evidence that you did something wrong.

Is generic semaglutide available in Canada, and will it be cheaper?

Health Canada authorized the first generic semaglutide injection in April 2026 for type 2 diabetes, and a second generic — a generic of Wegovy, approved for chronic weight management — at the end of June 2026, with more submissions under review. Generic competition generally lowers prices over time, though an authorization is not the same as stock on your pharmacy's shelf, and neither one is plan coverage. Your prescriber and pharmacist can tell you whether it is relevant to you.

Does OHIP cover Ozempic or Wegovy?

OHIP covers physician and hospital services rather than prescription drugs. Drug coverage in Ontario runs through the Ontario Drug Benefit program, which covers semaglutide only under limited-use criteria for type 2 diabetes, not for weight management. The full picture, including private plans, is in how Ozempic coverage works in Ontario.

Is surgery cheaper than staying on medication?

That comparison is less useful than it looks. The two are funded differently, cost differently over time and suit different people. Cost belongs in the decision, but it is not the clinical part of it. More of the recurring questions we hear are answered on our FAQ page.

Can I go back on the medication later?

Many people do, and prescribers generally treat it as a normal part of managing a chronic condition rather than a setback. Whether and when it makes sense is a decision for you and your prescriber.

If cost is the reason, start with a conversation

Stopping a GLP-1 because the price stopped working is a common, ordinary situation, and it has more possible next steps than it feels like at the time — a plan re-check, a different medication, a publicly funded pathway, a later restart, or an assessment for surgery. Which of those fits depends entirely on you.

This page is general education, not medical advice, and reading it does not create a patient relationship. It cannot tell you whether a particular medication, dose or treatment is right for you, and it is not a coverage determination. Decisions about starting, stopping, changing or restarting any medication belong to you and the clinician who prescribes it. Individual results vary. Consult with Dr. Gmora for a personalized assessment. If you develop concerning symptoms, contact your own physician or seek urgent care rather than looking for the answer online.

When you are ready to work out what comes next — medication you can sustain, a surgical pathway, or a clear answer that neither is right for you — you can book a consultation with Dr. Scott Gmora, MD FRCSC FACS. The Sleeve Clinic prescribes and co-manages weight-management medication as well as performing sleeve gastrectomy, so someone who has come off a GLP-1 over money and has no interest in an operation still has somewhere to take the question. Consultations are available in Toronto and virtually within Canada. A conversation is a reasonable first step and commits you to nothing.

More about the surgeon · eligibility assessment